Format
Sort by
Items per page

Send to

Choose Destination

Best matches for TAVABOROLE/AE:

Efinaconazole and Tavaborole. Poulakos M et al. J Pharm Pract. (2017)

Tavaborole topical solution, 5% for the treatment of toenail onychomycosis. Zane LT et al. Drugs Today (Barc). (2015)

Tavaborole - a treatment for onychomycosis of the toenails. Gupta AK et al. Expert Rev Clin Pharmacol. (2016)

Search results

Items: 1 to 20 of 21

1.

Common drug-drug interactions in antifungal treatments for superficial fungal infections.

Gupta AK, Versteeg SG, Shear NH.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):387-398. doi: 10.1080/17425255.2018.1461834. Epub 2018 Apr 26. Review.

PMID:
29633864
2.

Utility of Boron in Dermatology.

Jackson DG, Cardwell LA, Oussedik E, Feldman SR.

J Dermatolog Treat. 2017 Aug 9:1-20. doi: 10.1080/09546634.2017.1363850. [Epub ahead of print]

PMID:
28789577
3.
4.

New Antifungal Agents and New Formulations Against Dermatophytes.

Gupta AK, Foley KA, Versteeg SG.

Mycopathologia. 2017 Feb;182(1-2):127-141. doi: 10.1007/s11046-016-0045-0. Epub 2016 Aug 8. Review.

PMID:
27502503
5.

Tavaborole - a treatment for onychomycosis of the toenails.

Gupta AK, Versteeg SG.

Expert Rev Clin Pharmacol. 2016 Sep;9(9):1145-52. doi: 10.1080/17512433.2016.1206467. Epub 2016 Jul 14. Review.

PMID:
27347905
6.

Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: II. Prenatal and Postnatal Developmental Toxicity and Maternal Function Study.

Ciaravino V, Coronado D, Lanphear C, Hoberman A, Chanda S.

Int J Toxicol. 2016 Sep;35(5):543-57. doi: 10.1177/1091581816641938. Epub 2016 May 2.

PMID:
27138050
7.

Antifungal agents for onychomycosis: new treatment strategies to improve safety.

Zane LT, Chanda S, Coronado D, Del Rosso J.

Dermatol Online J. 2016 Mar 16;22(3). pii: 13030/qt8dg124gs. Review.

8.

Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.

Rosen T, Stein Gold LF.

Semin Cutan Med Surg. 2016 Mar;35(3 Suppl 3):S51-5. doi: 10.12788/j.sder.2016.009.

PMID:
27074700
9.

Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: I. Reproductive and Developmental Toxicity Studies.

Ciaravino V, Coronado D, Lanphear C, Hoberman A, Chanda S.

Int J Toxicol. 2016 Sep;35(5):530-42. doi: 10.1177/1091581816639113. Epub 2016 Apr 4.

PMID:
27044640
10.

Efinaconazole and Tavaborole.

Poulakos M, Grace Y, Machin JD, Dorval E.

J Pharm Pract. 2017 Apr;30(2):245-255. doi: 10.1177/0897190016630904. Epub 2016 Jul 8. Review.

PMID:
26873506
11.

Novel investigational therapies for onychomycosis: an update.

Gupta AK, Studholme C.

Expert Opin Investig Drugs. 2016;25(3):297-305. doi: 10.1517/13543784.2016.1142529. Review.

PMID:
26765142
12.

Spotlight on tavaborole for the treatment of onychomycosis.

Jinna S, Finch J.

Drug Des Devel Ther. 2015 Nov 20;9:6185-90. doi: 10.2147/DDDT.S81944. eCollection 2015. Review.

13.

Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.

Zane LT, Plattner J, Chanda S, Coronado D, Merchant T, Alley MR, Gupta AK.

Drugs Today (Barc). 2015 Oct;51(10):599-607. doi: 10.1358/dot.2015.51.10.2401004. Review.

PMID:
26583302
14.

New Topical Therapeutic Options in the Management of Superficial Fungal Infections.

Zeichner JA.

J Drugs Dermatol. 2015 Oct;14(10 Suppl):s35-41. Review.

PMID:
26461833
15.

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.

Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, Wiltz H, Zane LT, Pollak R.

J Am Acad Dermatol. 2015 Jul;73(1):62-9. doi: 10.1016/j.jaad.2015.04.010. Epub 2015 May 5.

16.

Tavaborole 5% solution for onychomycosis.

Gupta AK, Daigle D, Abramovits W.

Skinmed. 2015 Jan-Feb;13(1):55-8. No abstract available.

PMID:
25842473
17.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.

J Drugs Dermatol. 2014 Sep;13(9):1124-32.

PMID:
25226015
18.

Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies.

Ciaravino V, Coronado D, Lanphear C, Shaikh I, Ruddock W, Chanda S.

Int J Toxicol. 2014 Sep-Oct;33(5):419-27. doi: 10.1177/1091581814545245. Epub 2014 Sep 7.

PMID:
25201897
19.

Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.

Gupta AK, Daigle D.

Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42. doi: 10.1586/14787210.2014.915738. Epub 2014 Jun 4. Review.

PMID:
24894552
20.

An assessment of the genetic toxicology of novel boron-containing therapeutic agents.

Ciaravino V, Plattner J, Chanda S.

Environ Mol Mutagen. 2013 Jun;54(5):338-46. doi: 10.1002/em.21779. Epub 2013 Apr 26.

PMID:
23625818

Supplemental Content

Loading ...
Support Center